Dose Escalation Offers Limited Benefit After Ustekinumab Failure : Gastroenterology | Jul 2026

Introduction:

Ustekinumab is an established treatment for moderate-to-severe Crohn’s disease, but secondary loss of response remains a significant clinical challenge during long-term therapy. In routine practice, dose intensification strategies are frequently employed to recapture disease control, although high-quality prospective evidence supporting specific escalation approaches has been limited.

Problem Statement:

When patients lose response to ustekinumab maintenance therapy, clinicians often intensify treatment by shortening dosing intervals or administering intravenous reinduction. However, the optimal intensification strategy and its long-term effectiveness have remained uncertain, leading to substantial variability in clinical practice.

Summary:

The REScUE study is the first prospective randomized trial specifically evaluating ustekinumab dose-intensification strategies in Crohn’s disease patients experiencing secondary loss of response. Following intravenous reinduction, patients were assigned to either intensified subcutaneous dosing every four weeks or standard maintenance dosing every eight weeks. At 48 weeks, steroid-free clinical remission rates were low and did not differ significantly between the two treatment strategies. Likewise, safety outcomes were comparable, with similar rates of serious adverse events across both groups. These findings suggest that increasing the frequency of ustekinumab administration after intravenous reinduction does not provide additional clinical benefit compared with continuing standard eight-week maintenance dosing. The study challenges the common assumption that more intensive dosing necessarily improves outcomes in patients with secondary loss of response. Importantly, the overall modest remission rates observed indicate that many patients who lose response to ustekinumab may require alternative therapeutic approaches rather than further dose escalation. From a practical standpoint, the results support a more selective use of intensified ustekinumab schedules, potentially reducing treatment burden and healthcare costs without compromising efficacy. Overall, the REScUE trial provides important prospective evidence that routine escalation to four-week ustekinumab dosing after intravenous reinduction may not improve long-term outcomes in Crohn’s disease, highlighting the need for individualized treatment decisions and consideration of alternative therapeutic mechanisms when secondary loss of response occurs.